BCL-6 is a transcription factor essential for germinal centre B-cell development. The BCL-6 gene is involved in diffuse large-cell lymphoma and overexpressed in other types of non-Hodgkin's lymphoma and in high-grade breast cancer. BCL-6 is a transcriptional repressor whose N-terminal POZ domain mediates protein-protein interactions to exert its effects. Reasoning that disruption of POZ domain-mediated interactions may be an effective route to antagonizing the effects of BCL-6 in lymphoma, we screened a library for peptide aptamers that specifically bind to BCL-6 POZ and not the POZ domains of related proteins and describe here the first of these reagents, Apt48. Apt48 binds BCL-6 POZ in a manner distinct from the transcriptional corepressor SMRT, yet was found to prevent BCL-6-mediated repression of a luciferase reporter gene. Apt48 also reproduced several previously validated effects of BCL-6 inhibition. Notably, expression of the differentiation markers CD69, Blimp-1 and cyclin D2 was increased in B-cell lines when Apt48 was expressed. We also show that expression of Apt48 restores cytokine-mediated growth arrest to BCL-6 overexpressing cells. Thus, we have identified a peptide aptamer that affects a function of BCL-6 that is required to prevent differentiation of proliferating B cells.
Introduction
BCL-6 is a transcription factor which is normally expressed at high level in lymph node germinal centres (Cattoretti et al., 1995; Onizuka et al., 1995) . The BCL-6 gene was cloned from chromosomal translocations in diffuse large-cell lymphoma (Baron et al., 1993; Ye et al., 1993) , suggesting that it has a role in the causation of this disease, and is expressed in other lymphoproliferations, for example follicular lymphoma, Burkitt's lymphoma and B-cell predominant Hodgkin's disease and a number of breast cancers (Logarajah et al., 2003) .
Analysis of mice bearing homozygous deletions of the BCL-6 locus demonstrates an essential role in germinal centre formation and humoral immunity (Dent et al., 1997; Fukuda et al., 1997; Ye et al., 1997) . BCL-6 expression promotes proliferation and inhibits differentiation and apoptosis of B-cell lines (Niu et al., 1998; Shaffer et al., 2000) . Conversely, expression of an inducible dominant-negative BCL-6 (Shaffer et al., 2000) led to the upregulation of genes associated with B-cell differentiation, for example Blimp-1, and cell death in the Burkitt's lymphoma cell line Raji (Turner et al., 1994) . Similar results were obtained in another Burkitt's lymphoma cell line where crosslinking of surface IgM led to downregulation of BCL-6 and apoptosis (Niu et al., 1998) . Thus BCL-6 allows proliferation and its downregulation is associated with differentiation and cell death. These data suggest that BCL-6 may be a therapeutic target in lymphoma.
At the molecular level, the carboxy-terminus of BCL-6 comprises a DNA-binding domain of six zinc fingers, which recognize the same consensus sequence as that of the signal transducers and activators of transcription (STAT) family of transcription factors (Dent et al., 1997) . BCL-6 can bind to STAT6 (Dent et al., 1997; Harris et al., 1999) and STAT3 (Reljic et al., 2000) binding sites, suggesting that it may function in part by antagonizing STAT signalling. The effector portion of BCL-6 is a POZ/BTB domain (Pox virus and zinc-finger/bric-a-brac tramtrack broad complex (Bardwell and Treisman, 1994) , hereafter, referred to as the POZ domain) located at the amino terminus of the molecule. POZ domains mediate transcriptional repression (Chang et al., 1996) and this is generally, although not exclusively (Deltour et al., 1999) , achieved by association with the corepressor proteins N-CoR and SMRT (Huynh and Bardwell, 1998) , which in turn recruit histone deacetylases (Dhordain et al., 1998) . As well as these heterologous protein-protein interactions, POZ domains are able to homodimerise, and in some cases heterodimerise (Davies et al., 1999; Dhordain et al., 2000 and references in Table 1 ). It has been postulated that overexpression of one POZ domaincontaining protein may lead to heterodimerization with another POZ domain-containing protein, resulting in loss of function and either physiological or pathological effects (Bardwell and Treisman, 1994) . This mechanism could plausibly contribute to pathology in cells overexpressing BCL-6 as a result of chromosomal translocation.
Elucidation of the crystal structure of the homodimer formed by the POZ domain of PLZF (promyelocytic leukaemia zinc finger; Ahmad et al., 1998; Melnick et al., 2000) has demonstrated that there is a large interface at which the components of the homodimer interact. A relatively small charged pocket, formed from both halves of the dimer, is required for recruitment of corepressor molecules and is hence essential for POZ domain function. A more recent structure of the BCL-6 POZ domain shows that a peptide from each of two SMRT proteins bind symmetrically to the BCL-6 POZ homodimer (Ahmad et al., 2003) . While the present work was in progress, structural information was used to design a SMRT peptide derived inhibitor of BCL-6 function, called BBD (BTB binding domain) (Polo et al., 2004) .
Here, we describe the isolation of peptide aptamers (peptides whose amino-and carboxy-termini are anchored in the context of a scaffold protein; Colas et al., 1996) against BCL-6. The role of the scaffold protein is first, to reduce the range of conformations that can be adopted by a given sequence of amino acids; second, to display these conformationally constrained peptides on the surface of a larger molecule; and third, to stabilize the presented peptide in the cellular environment (Colas et al., 1996) . As is the case in proteins that occur in nature, different peptide sequences adopt different conformations. Libraries of constrained peptides therefore represent a range of structures that can be screened for biological interactions, with a view to identifying molecules with desired effects. Constrained peptides are able to bind to their target proteins with specificities and affinities comparable to antibodies (Colas et al., 1996) and have been used to interfere with protein function in a number of cellular pathways (see Crawford et al., 2003) . Like the SMRT-derived peptide, by binding to the POZ domain of BCL-6 peptide aptamers may specifically compete for individual protein-protein interactions in vivo. In contrast to the SMRT-derived peptide, peptide aptamers identified in our screen may bind to any of several protein-interaction surfaces of the BCL-6 POZ and may therefore identify other ways of interfering with BCL-6 function. We characterize the first of the peptide aptamers we have isolated, called Apt48. Our data show that Apt48 binds to BCL-6 POZ in a manner distinct from that used by the SMRT peptide. Apt48 is able to interfere with BCL-6 mediated repression in three distinct cellular assays, and restores on BCL-6 overexpressing cells the ability to growth arrest. Our results confirm that the POZ domain of BCL-6 is a valid drug target and that its function may be inhibited by targeting sites other than the groove where SMRT-related corepressors bind. The exact mechanism of action of Apt48 remains to be determined (see Discussion) and future work will be required to fully exploit its implications for drug discovery.
Materials and methods
Plasmids and cloning DNA manipulations were performed as described by Sambrook and Russell (2001) . Oligonucleotides were from SigmaGenosys (Pampisford, UK). All enzymes were from New England Biolabs (Hitchin, UK) and competent cells were from Stratagene (UK). Plasmid and nucleotide DNA was prepared and cleaned using the appropriate Qiagen (Crawley, UK) kits. FLAG-tagged full-length BCL6 was a kind gift from Dr Paul A. Wade, Emory University School of Medicine, Atlanta. Sequences corresponding to the POZ domains of BCL-6, and BCL-6b were PCR amplified from mouse spleen cDNA, and of PLZF and BACH2 from plasmids kindly supplied by Dr A. Zelent, Institute of Cancer Research, London and Dr J.V. Melo, Department of Haematology, Imperial College London, respectively. The PCR products were cloned as in frame fusions to the DNA-binding domain of Escherichia coli LexA in the yeast two-hybrid vectors pEG202 (bait) and in the case of pJG4-5 (prey; Gyuris et al., 1993) in frame with the Gal4 activation domain, using EcoRI sites present in both vectors. The sequence encoding full length BCL-6, where serines 333 and 334 are mutated to alanine residues, was cloned into SacIand BamHI-digested pCDNA3.1 myc/his þ (Invitrogen, Paisley, Scotland). The coding sequence of peptide aptamer number 48 from the screen (Apt 48) including the full coding sequence of E. coli thioredoxin A (TrxA) was PCR-amplified from the peptide aptamer prey vector pJM-1 (Colas et al., 1996) using a 5 0 primer containing a EcoRI restriction site (5 0 -GGAATTCCACCATGGCTA-GCGATAAAATTATTCAC) and a 3 0 primer containing a XbaI site (5 0 -GCTCTA GAGCGGC-AGGTTAGCGTC) and cloned into EcoRIand XbaI-digested pCDNA3.1B myc/his þ (Invitrogen). Similarly, Apt48 and TrxA coding sequences were PCR-amplified using a 5 0 primer containing a EcoRI site (5 0 -GGAATTC CACC-ATGGCTAGCGATAAAATTATTCAC) and a 3 0 primer containing a SacII site (5 0 -TCCCCGCGG-GGAC TAGGCCAGGTTAGCGTCGAG) and cloned into EcoRIand SacII-digested pIRES-DsRed2 (Clontech).
Peptide aptamer library construction and yeast two-hybrid techniques Yeast two-hybrid plasmids and strains were the kind gifts of Roger Brent (Molecular Sciences Institute, Berkeley, California, USA) and Erica Golemis (Fox Chase Cancer Centre, Rose et al. (1990) and yeast two-hybrid screening was as described by Gyuris et al. (1993) and Golemis et al. (1999) . Library construction and designed peptide aptamers were made following the protocols of Colas et al. (1996) .
Antibodies, immunoprecipitation and Western blotting All primary antibodies were from Santa Cruz (CA, USA).
Western blotting of mammalian cell lysates was performed using rabbit polyclonal antibodies N-3 or C-3 to BCL6. The myc epitope tag of Apt48 or thioredoxin or FLAG-tagged BCL6, expressed from pCDNA3.1 myc/his was detected using a myc-A14. Detection of Apt48 or TrxA in yeast lysates was performed using a monoclonal mouse antibody to the epitope tag derived from Influenza virus haemagglutinin (HA, using antibody F7). HRP-conjugated goat secondary antibodies were from Pierce and membranes were developed with ECL reagent (Amersham, Chalfont St Giles, UK). For immunoprecipitation experiments, U2os cells transfected (using GeneJuice, Novagen and OPTIMEM, Gibco-BRL) with FLAG and myc-tagged-BCL6 and myc-tagged-Apt 48 or -TrxA were lysed after 24 h of transfection for 15 min at 41C using a lysis buffer consisting of 0.5% Triton X-100, 10 mM Tris (pH 7.5), 10 mM NaCl, 3 mM MgCl 2 and supplemented with Complete Protease inhibitor cocktail (Roche Molecular Biochemicals) and dimethyl sulphoxide (Sigma). After centrifugation at 13 000 r.p.m. for 15 min, the supernatant was incubated with 20 ml prewashed anti-FLAG monoclonal antibody M2 beads (Sigma) and left overnight. Aptamer-BCL6 interactions were detected by washing the beads five times with the same lysis buffer followed by eluting the proteins bound to the beads in SDS sample buffer for SDS-PAGE and subsequent Western blotting with an anti-myc antibody.
Cell lines and cell culture U2os cells are an osteosarcoma cell lines that are not known to express BCL-6 and do not respond to cytokines. BCL1 cells are representative of immature B cells: they are cytokine responsive but do not express BCL-6. Ramos, Raji and Daudi cells are BCL-6 expressing human Burkitt's lymphoma lines. A20 cells are BCL-6 overexpressing mouse cells. All tissue culture media and supplements were from Gibco-BRL (Paisley, UK). 2-mercaptoethanol was from BDH (Poole, UK). Ramos, Raji, Daudi and A20 cell lines were maintained in RPMI 1640 media supplemented with 10% fetal calf serum (FCS) (HyClone) and penicillin (100 U/ml)/streptomycin (100 mg/ml) (pen/strep, final concentrations). BCL1 cells were cultured in RPMI 1640 with 15% FCS, 10 mM HEPES, 50 mM 2-mercaptoethanol and pen/strep. U2os cells were maintained in D-MEM supplemented with 10% FCS.
Transient transfection and immunofluorescence
Ramos cells were transfected with expression plasmids using the Nucleofector (Amaxa, Cologne, Germany) following the manufacturer's instructions. After overnight culture, transfected cells were seeded on poly-L-lysine-coated coverslips and fixed using 4% paraformaldehyde for 20 min at room temperature, washed three times with phosphate-buffered saline (PBS) containing 1% bovine-serum albumin (BSA), permeabilized for 30 min with 0.2% saponin in 1% BSA-PBS, blocked for 1 h with 10% normal goat serum, and incubated overnight at 41C with primary antibodies. CD69 expression was visualized directly using allophycocyanin (APC)-conjugated a-CD69 antibody (BD Biosciences, Cowley, UK), whereas peptide aptamer expression was visualized using aTrxA primary antibody (Sigma, Poole, UK) with fluorescein isothiocyanate-conjugated goat anti-rabbit secondary (Alexa 488, Molecular Probes, Paisley UK). Nuclear DNA was visualized with DAPI (4 0 ,6 0 -diamidino-2-phenylindole). Coverslips were mounted using Vectashield (Vectorlabs, Peterborough, UK). The cells were examined by confocal laser-scanning microscopy (Zeiss LSM 510).
Flow sorting, RNA extraction and RT-PCR Cell lines were transfected with peptide aptamers or empty thioredoxin scaffold expressed from mammalian expression vectors upstream of an IRES site and DSRed2. A measure of 5 mg of plasmid DNA was transfected by means of a Nucleofector, Kit T (Amaxa) using programmes O-17 for BCL1 and Ramos, and T-16 for A20 cells. After 24 h, cells expressing DSRed2 were collected by FACS for extraction of RNA and production of cDNA (Qiagen). Primers used were as follows: CD69 forward 5 0 -TATAACGGAAAATAGCTCTT CACATCT; CD69 reverse 5 0 -TGATTAGCTTCATTTTT CAGCCCAAT; Blimp-1 forward 5 0 -TGGACATGGAGGA CGCTGATATG; Blimp-1 reverse 5 0 -GCGCATCCAGTTGC TTTTCTCCTCA; CyclinD2 forward 5 0 -GCGTGGGAG CAGCCATCTGT; CyclinD2 reverse 5 0 -AGGTCAAC ATCCCGCACGTCTG. Actin was used as a loading control for the mouse A20 cells and GAPDH for the human cells. The mouse actin forward primer was 5 0 -AGGTCATCAC TATTGGCAACGA and mouse actin reverse 5 0 -CACTT CATGATGGAATTGAATGTAGTT. Human GAPDH primers are from Shaffer et al. (2000) 13:199-212 and were GAPDH forward: 5 0 -GGGCGCCTGGTCACCAGGGCTG and GAPDH reverse 5 0 -GGGGCCATCCACAGTCTTCTG. Real-time PCR was performed using the same primers and SYBRGreen to label PCR products, in an ABI Prism 7700 Sequence Detector, according to the manufacturers' instructions.
Luciferase reporter assay
The STAT3 reporter construct and assay used in this study was exactly as described by Reljic et al. (2000) . Transfection experiments were performed in duplicate and repeated three times. The combinations of plasmids transfected in each case are given in the figure legend.
Survival assay
The effects of peptide aptamers on cell survival was tested in BCL1 cells, which lack endogenous BCL-6, and the Burkitt's lymphoma cell lines Ramos, Raji and Daudi, which expresses BCL-6. Cells were transfected with combinations of plasmids constituting 5 mg of DNA in total and including pEGFP (BD Clontech) as a marker of transfection using a Nucleofector (Amaxa). The plasmid combinations used were (1) BCL-6 expression plasmid þ peptide aptamer expression plasmid þ pEGFP; (2) BCL-6 expression plasmid þ thioredoxin expression plasmid þ pEGFP; (3) peptide aptamer expression plasmid þ pEGFP; and (4) thioredoxin expression plasmid þ pEGFP. After transfection, cells were cultured in complete medium without other additives and, in the case of BCL1 cells, in medium containing interleukins-2 and -5 for up to 3 days. The proportion of viable cells expressing EGFP, a marker for transfection, was measured on a FACScalibur (BD Biosciences) and normalized relative to the value at day 1 after transfection. Ramos, Daudi and Raji cells were transfected with peptide aptamer expression plasmid þ pEGFP or thioredoxin expression plasmid þ pEGFP and the effect of transfection on cell survival was measured as above.
Results

Yeast two-hybrid analysis of POZ domain interactions
We wished to identify peptide aptamers that would bind to the independently folding POZ domain of BCL-6 in a yeast two-hybrid screen. Our goal was to obtain peptide aptamers that bind to the POZ domain of BCL-6 but not that of other selected transcription factors (BACH2, BCL-6b, and PLZF), that are able to heterodimerize with BCL-6 (Table 1) , are expressed in B-cells or, in the case of BCL-6b have a virtually identical DNA binding site to BCL-6. In order to confirm that the BCL-6 POZ domain behaved appropriately in yeast, we asked whether we could reproduce in the yeast two-hybrid system known interactions of BCL-6 POZ with these POZ domains (Figure 1a) . We confirmed in eukaryotic cells the previously reported homodimerization of the POZ domains of BCL-6 and of PLZF shown in crystal structures (Ahmad et al., 1998; Melnick et al., 2000) . We also observed previously unreported interactions between POZ domains (compare Figure 1a and Table 1) . Thus BACH2 appears to interact with all the POZ domains tested, including itself and BCL-6 POZ. We also note an interaction between the POZ domains of BCL-6 and BCL-6b. Finally, we note that homodimerization between the POZ domains, for example, of PLZF and BCL-6 is of greater strength than formation of hetero-dimers for example of BCL-6 and BACH2 or BACH2 and BCL-6b in this assay.
Peptide aptamers that bind specifically to the POZ domain of BCL-6 To screen for peptide aptamers that specifically bind the POZ domain of BCL-6, we first constructed a yeast twohybrid library of random peptides 10 amino-acid residues in length using the well characterized E. coli thioredoxin (TrxA) scaffold. Although the standard length for the peptide moiety of peptide aptamers is 20 amino-acid residues (Colas et al., 1996) , we reasoned that a shorter peptide would give rise to more stable peptide aptamers by minimizing disruption to the scaffold. Shorter peptides may also lead to more stable The expression of the peptide aptamers and cyclin D prey fusion proteins is induced by galactose present in the growth medium, allowing interactions to be measured by the development of a blue colour following induction of the LacZ reporter gene. Apt48 binds most strongly to the BCL-6 POZ and shows no significant cross-reactivity, whereas Apt52 and 58 appear to bind to CDK4 as well as to BCL-6 POZ. Apt7/130 is the most specific binder, but does not bind BCL-6 POZ as strongly as Apt48. (c) BCL-6 and Apt48 can be co-immunoprecipitated from cells. Constructs carrying Flag-and myc-tagged BCL-6 and myc-tagged Apt48 or thioredoxin were co-transfected into U2os cells. BCL-6 was immunoprecipitated from whole cell lysates (WCL) with an anti-Flag tag antibody and the immunoprecipiatates (IP) probed with an anti-myc antibody. Lanes 1 and 3 are from cells cotransfected with Apt48 and BCL-6, while lanes 2 and 4 are from cells co-transfected with TrxA and BCL-6. The band marked with an asterisk that appears in the IP lanes is the antibody light chain. (d) Sequences of the peptide aptamers isolated in the screen. The hexameric restriction/ligation sequence used to insert oligonucleotides into the TrxA open reading frame encodes a glycine-proline (GP) dipeptide, given in lower case. In the case of Apt7, an inframe STOP codon encoded by the second of two inserted oligonucleotides results in a truncated form of TrxA protein, and the encoded peptides are presented, unconstrained, at the carboxyl terminus of the fusion protein.
A peptide aptamer to antagonize BCL-6 function A Chattopadhyay et al peptide conformations. Both of these effects may lead to a greater efficacy in screening. We screened 250 000 peptide aptamers for their ability to bind to a bait comprising the first 122 amino acids of BCL-6. We isolated seven positive hits. We sequenced the thioredoxin/peptide open reading frame for each plasmid and identified four unique peptide sequences (Figure 1 , panels b and d). One of these (Apt 7) is not constrained and appears to be the result of the fusion of two peptideencoding oligonucleotides during library construction, the second of which encodes an in-frame stop codon. Its apparent high specificity for BCL-6 POZ may reflect a large surface area of interaction of the unconstrained peptide moiety, potentially giving rise to a greater number of interactions between the peptide and the target. Apt52 shows weak binding to both PLZF and BACH2, as well as to the unrelated CDK4 protein (Figure 1b) , and was not pursued further. Apt48, 58 and 7 (which has the same sequence as Apt130) all show a high degree of specificity for BCL-6 (Figure 1b ). Apt58 did not show activity in our first functional assay (se below) and was not pursued further. Apt48 shows the highest apparent affinity in this assay, approximating the apparent strength of interaction between BCL-6 POZ monomers (compare Figure 1a and b. Such a comparison is possible because we transform equal amounts of plasmid into yeast in each experiment, and always include standard controls, such as the androgen receptor and the naturally dimerizing Cyclin D and CDK4, which allows us to compare signal intensities between plates. In addition, we confirm equal expression levels of each peptide aptamer in the cells by Western blotting; data not shown). In order to validate the yeast two-hybrid interaction, we showed that Apt48 (Figure 1 panel c, lanes 1 and 3), but not thioredoxin (lanes 2 and 4) could be coimmunoprecipitated with Flag-tagged full length BCL-6 (Fujita et al., 2004) from U2os cells (Figure 1c ). The hit rate in our screen (1:10 5 ) is identical to that observed with 20-mer peptide insert libraries. If we assume that BCL-6 POZ is a representative yeast two-hybrid bait (an untested assumption), this hit rate would indicate that, at least in yeast, thioredoxin molecules are likely to be equally stable with 10 or 20 residue peptide inserts. On the basis of these observations, Apt48 was chosen as the focus of our subsequent work.
Apt48 binds outside the known corepressor and dimerization interfaces
The crystal structure of the POZ domain of BCL-6 bound to a peptide derived from the SMRT corepressor show at least two distinct BCL-6 surfaces that may be susceptible to manipulation (Ahmad et al., 2003) . One of these allows the dimerization of BCL-6 POZ, and the other allows interaction with a relatively small surface of the corepressor. Melnick et al. (2002) have suggested the existence of a third surface that forms a charged pocket whose integrity is required for BCL-6 function, but no interaction at this surface has been demonstrated unequivocally. We tried to find out whether Apt48 binds to POZ in the same manner as SMRT. Firstly, we inserted residues into the first half of the peptide moiety of Apt48, creating a designed (Des) hybrid peptide aptamer between Apt48 and SMRT BBD sequences (Figure 2a) . Because it is difficult to predict whether the inserted Des peptide, when constrained by the thioredoxin scaffold, will adopt the appropriate conformation to lie in the POZ groove revealed by Ahmad et al. (2003) , we inserted both one and two copies of the Des sequence into thioredoxin, rationalizing that the extra length would minimize the conformational constraints imposed by the scaffold. We were unable to detect an interaction between Des and BCL-6 POZ (data not shown). In a second experiment, we inserted the BBD peptide derived from SMRT by Ahmad et al. (2003) into the thioredoxin scaffold. This SMRT/BBD peptide aptamer was able to bind to BCL-6 POZ ( Figure 2b ) and interaction was abolished by the N21 K mutation that abolishes SMRT binding to BCL-6 (Ahmad et al., 2003) . Importantly, the N21 K mutation was without effect on Apt48 interaction with BCL-6 POZ ( Figure 2b ). Together, these data lead us to conclude that Apt48 binds to POZ in a manner different from the SMRT peptide. In an initial attempt to identify the Apt48 binding site, we sought unique regions of sequence complementarity between Apt48 and BCL-6, that are not present in PLZF or other POZ domains we had tested, with the idea that mutation of critical residues in such regions of BCL-6 would abolish Apt48 binding. The best candidate for such a region comprised residues P80-L86 of BCL-6 POZ (Figure 2a) , and our hypothesis was that E81 and C84 of BCL-6 POZ may form bonds with the arginine and cysteine residues of Apt48 (Figure 1d ). However, mutation of these residues in BCL-6 (E81K and C84N) failed to affect the interaction between BCL-6 POZ and Apt 48 (Figure 2b ), indicating that this surface is not likely to be important in recruitment of Apt48. We therefore adopted an open-ended approach, using yeast twohybrid interaction mapping to determine which surface of BCL-6 POZ is being targeted by Apt48. We created seven fragments of BCL-6 POZ ( Figure 2c ) that correspond to the main elements of secondary structure in each monomer in the crystal structure (Ahmad et al., 2003) . We predicted that fragment 1 (containing the first beta strand, bl and alpha helix a1) would interact with both POZ and the BBD, and this was indeed what we observed (Figure 2c ). Fragment 3 (a2 and a3), which interacts with the opposing monomer in the structure, also provides supporting interactions for BBD binding in the structure. We could detect a weak interaction between fragment 3 and POZ, but not between fragment 3 and BBD (Figure 2c ). Fragment 1 and 3 did not interact with Apt48. Consistent with this, the N21 K mutation that maps in fragment 1 does not inhibit binding of Apt48 (Figure 2b ). (Figure 2c ). Fragments 4 (b4), 6 (b5 and a5) and 7 (a6) did not interact with POZ, BBD or Apt48 (Figure 2c ). Contrary to expectations, we observed interactions between POZ and fragments 2 (b2 and b3) and 5 (a4). Fragment 2 was also able to interact with Apt48, but not BBD. Because fragment 2 is the only one that is able to interact with Apt48 in this assay, we conclude that fragment 2 is necessary and may be sufficient for Apt48 binding to POZ. In the structure, this fragment lies at the top of the monomer and contributes to the formation of the charged pocket identified by Melnick et al. (2002) , whereas the SMRT peptide binds in a groove at the opposite surface (Ahmad et al., 2003) .
Apt48 promotes the expression of differentiation markers in BCL-6 expressing B cell lines BCL-6 expression has been suggested to inhibit the terminal differentiation of B cells (Reljic et al., 2000) . BCL-6 inhibition experiments suggest that BCL-6 functionally downregulates the expression of a range of genes including CD69, CD44, BLIMP-1 and cyclin-D2 (Shaffer et al., 2000) . We therefore asked whether Figure 2 The mechanism of action of Apt48 may not involve displacement of the SMRT corepressor from BCL-6 POZ. (a) Sequence alignments of the SMRT BBD sequence that is known to bind to the POZ domain of BCL-6 (top line; Polo et al., 2004) , the unique sequence of Apt48 (middle line), the designed version of Apt48 intended to mimic SMRT ('Des': third line) and a sequence for BCL-6 with complementarity to Apt48. Identical residues are highlighted in red, including the cysteine residue that were proposed to form a crossbridge in the Apt48-POZ complex in our first model, whereas residues of POZ that are complementary to residues in Apt48 are highlighted in green and the glycine-proline motif that flanks peptides inserted into the peptide aptamer scaffold is given in lower case. (b) Yeast two-hybrid interaction matrix to show that a mutation in BCL-6 POZ (N21K) that abolishes binding to SMRT-BBD does not affect binding to Apt48 or to POZ. Mutation of other residues of POZ (E81K and C84N) to the corresponding residues present in PLZF also do not affect Apt48 or POZ binding. pJM-1 expresses E coli thioredoxin and differs from Apt48 and BBD only in not carrying an inserted peptide. (c) Seven fragments of BCL-6 POZ corresponding to the elements of secondary structure revealed by Ahmad et al. (2003) were cloned as yeast two-hybrid baits and their interaction with preys consisting of Apt48, the SMRT-BBD peptide aptamer or BCL-6 POZ itself was determined. Fragment 1 interacted with POZ and with BBD, as predicted by the crystal structure, but did not recognize Apt48. Fragment 2 did bind Apt48, and also recognized POZ, but not the BBD. Fragment 3 shows weak interaction with POZ but not with Apt48 or BBD. Fragment 5 was a trans-activating bait whose interaction with POZ was strong enough to be seen above the trans-activation signal, but it was not possible to determine whether there was an interaction with Apt48 or BBD (ND: not determined). Fragments 4, 6 and 7 do not interact with POZ, BBD or Apt48 in this assay. the expression of Apt7, Apt48 or Apt58 in BCL-6 overexpressing Ramos cells would affect the expression of BCL-6 target genes. In a first experiment, we took advantage of the fact that CD69 is a cell-surface protein and performed FACS analysis of Ramos cells stained with APC-labelled anti-CD69 antibodies after transfection with Apt48 or control plasmids. We consistently obtained increases in CD69 labelling in the Apt48 transfected population compared to thioredoxin controls (data not shown). To correlate these increases with the expression of peptide aptamer in the cells, we turned to immuno-cytochemistry, staining cells for both peptide aptamer or thioredoxin using an anti-TrxA antibody and for CD69, using APC-labelled anti-CD69 antibodies. This allowed us to count only cells that had been transfected with peptide aptamer. In blind experiments, we found that whereas less than 5% of cells transfected with thioredoxin expressed CD69, more than 70% of cells transfected with Apt48 were positive for CD69 (Figure 3b ). It is noteworthy that the strength of induction of CD69 did not correlate with the amount of Apt48 detected in the same cell. We infer from this that low levels of Apt48 are sufficient to cause a phenotype: once BCL-6 function has been inhibited, the phenotype is not enhanced by further increasing Apt48 levels. Apt7 and Apt58 did not show significant effects in these assays and were not pursued further.
We extended this result to other BCL-6 target genes, Blimp-1 and cyclin D2 (Reljic et al., 2000; Shaffer et al. , Figure 3 The expression of Apt48 in cells relieves transcriptional repression. (a) Ramos cells normally express low levels of CD69, which are undetectable in this immunofluorescent assay and are not increased by expression of thioredoxin (left-hand side panels). In contrast, cells expressing Apt48 show significant levels of CD69 expression (right-hand side panels). CD69 expression is shown in red, and thioredoxin or Apt48 protein is shown in green. Nuclear DNA is stained blue, and the three panels are merged in the bottom right hand image of each set. (b) Ramos cells transfected with thioredoxin or peptide aptamer as above were processed for immunofluorescence and the samples anonymized before being independently counted by two individuals. As the data did not differ significantly, the two sets of data were combined, and are presented as the percentage of green (peptide aptamer or thioredoxin expressing) cells that were also expressing detectable levels of CD69. (c) Mouse A20 (left hand pair of each set of 4) or human Ramos (right hand pair of bars) transfected with expression constructs for either Apt48 (grey bars) or thioredoxin (black bars) upstream of an internal ribosome entry site and the ORF encoding red fluorescent protein were isolated by flow cytometry, lysed and mRNA levels measured by Real Time-PCR. When normalized to the loading control (actin for mouse, GAPDH for human cells), the mRNA levels for three known BCL-6 target genes (CD69, BLIMP-1 and Cyclin D2) show significant increase in cells expressing Apt48 when compared to those expressing empty scaffold (thioredoxin) alone. The increases range from 7 (CD69 in mouse A20 cells) to 15 fold (Blimp-1 in mouse cells).
A peptide aptamer to antagonize BCL-6 function A Chattopadhyay et al 2000) using both Ramos cells as before and A20 cells, derived from a mouse B-cell lymphoma, that express BCL-6 as well as activation-induced deaminase (AID) and surface IgG and thus have many of the characteristics of germinal centre cells. Using RT-PCR to analyse effects of Apt48 on gene transcription, we were able to confirm that peptide aptamer expression causes CD69, Blimp-1 and Cyclin D2 mRNA levels to increase over background in cells expressing the peptide aptamer in both Ramos and mouse A20 cells (data not shown). We confirmed these results using real-time PCR (Figure 3c ). The greatest effect we observed upon expression of Apt48 was on the Blimp-1 transcript, where Apt48 induced a 15-fold greater expression of Blimp-1 in mouse cells, and a 10-fold greater increase in human cells, than did TrxA alone. CD69 transcript appeared to be the least affected by Apt48, which induced a sevenfold increase in de-repression in mouse, and an eightfold effect in human cells. Together, these data indicate that Apt48 is able to antagonize BCL-6-mediated repression at a number of different promoters, including at genes that are markers or regulators of B-cell differentiation. These data also indicate that Apt48 is able to antagonize both the human and the mouse BCL-6 protein.
Apt48 functionally antagonizes BCL-6 activity in a cell model of transcriptional repression We wished to ask whether Apt48 was able to directly affect BCL-6 activity within cells. We chose to work in undifferentiated BCL1 cells that do not normally express BCL-6. This allowed us to confirm whether the effect of Apt48 was dependent upon the expression of BCL-6. We have previously shown that expression of exogenous BCL-6 in these cells is able to repress the interleukin 2/5-dependent expression of a luciferase reporter gene regulated by STAT3 binding sites (Reljic et al., 2000) . Accordingly, we co-transfected cells with reporter constructs and combinations of BCL-6 and Apt48 or empty vectors (Figure 4) . Cells lacking BCL-6 show a 2.5-fold upregulation of luciferase activity when challenged with interleukins-2 and -5, regardless of whether or not they express Apt48, confirming that any effects of Apt48 on transcriptional regulation require the presence of BCL-6. Expression of BCL-6 abolishes interleukin-mediated reporter gene induction. BCL-6-mediated repression of reporter gene induction is reversed by co-expression of Apt48, indicating that this peptide aptamer is able to inhibit BCL-6 function in this system.
Apt48 restores growth arrest on BCL-6 expressing B cells
An important observation has been that BCL-6 expression correlates with the proliferation of undifferentiated B cells in germinal centres, and BCL-6 expression has been suggested to inhibit terminal differentiation of B cells (Shaffer et al., 2000) . A key test for our peptide aptamer was therefore that it be able to confer on BCL-6 expressing, proliferating B cells the ability to growth arrest in response to cytokines. Accordingly, we transfected BCL1 cells with a plasmid encoding EGFP (as a marker for transfection) either alone, or with BCL-6, or with BCL-6 and either thioredoxin or Apt48 (Figure 5a and b) . At 3 days after transfection, the numbers of GFP-expressing cells was determined, and representative curves of three independent replicates are shown in Figure 5a . These data indicated that neither BCL-6 nor Apt48 affects the growth or survival of BCL1 cells in the absence of signals that normally regulate B-cell proliferation or differentiation. In contrast, when transfected cells were treated with cytokines that, in vivo, are thought to promote B-cell differentiation (or apoptosis of unselected B cells), cells expressing EGFP alone arrested, whereas cells expressing BCL-6 did not, and indeed appeared to undergo more than two rounds of population doubling (Figure 5b ). These data are consistent with an inhibition of differentiation by BCL-6. The combination of thioredoxin with BCL-6 did not alleviate this effect, also allowing cells to undergo more than two rounds of population doubling in three days. In contrast, Apt 48 completely abrogated the effect of BCL-6, making BCL1 cells once again sensitive to cytokine signalling (Figure 5b) .
The final test was to ask whether Apt48 could prevent the proliferation of MYC-overexpressing germinal centre-derived Burkitt's lymphoma cell lines that express BCL-6. For this experiment, we used Ramos (BCL-6 expressing, EBV À ; Figure 5c ), Daudi and Raji cells (the latter two cell lines also express BCL-6 and are infected with EBV; Figure 5d and e, respectively). The cells were transfected either with a GFP expression plasmid, as a marker for transfection, or with GFP and thioredoxin (the empty peptide aptamer scaffold) or with GFP and Apt48. Although both GFP and thioredoxin Figure 4 Apt48 can antagonize BCL-6 mediated gene repression in an exogenous system. The interleukin-dependent expression of a firefly luciferase reporter gene in transfected BCL1 cells is dependent on STAT3 binding sites, and can be repressed by BCL-6. Each pair of bars shows luciferase activity in the absence (left hand bar) and presence (right hand bar) of interleukins 2 and 5. In the absence of BCL-6, luciferase activity is induced by interleukin treatment ('vector alone') and this is not impaired by expression of Apt48 ('vector þ Apt48'). Expression of BCL-6 prevents interleukin-mediated induction of luciferase ('vector þ BCL-6'), unless Apt48 is also expressed, in which case interleukin-mediated induction of luciferase is restored ('BCL-6 þ Apt48').
transfections have some effect on cell viability, Apt48 was effective at inhibiting the growth of BCL-6 expressing cells, achieving greater than 40% reduction in cell number compared to controls in each cell line over the period of 3 days of the experiment.
Together, these data strongly suggest that Apt48 can interfere with BCL-6 function. In the light of the identification of Apt48 as a specific yeast two-hybrid interactor with the POZ domain of BCL-6, of the fact that Apt48 only affects transcription in cells that express BCL-6, and only affects cell viability in the presence of cytokines, we infer that Apt48 is mediating its effects by interfering directly with BCL-6 function.
Discussion
Since its discovery as a translocation partner of the immunoglobulin heavy chain in diffuse B-cell lymphoma (Baron et al., 1993; Ye et al., 1993) there has been intensive study of the biology of BCL-6 and much is now known about the molecular mechanisms by which it regulates the expression of target genes (Dent et al., 1997; Harris et al., 1999; Shaffer et al., 2000) . Functional studies demonstrate that BCL-6 allows cell proliferation but prevents B-cell terminal differentiation (Niu et al., 1998; Reljic et al., 2000; Shaffer et al., 2000) and this suggests a means by which its constitutive expression Figure 5 Apt48 reverses BCL-6 mediated resistance to cytokine-mediated growth arrest in BCL1 cells. (a and b) The growth of BCL1 cells expressing either GFP alone (~) or GFP and BCL-6 (m), GFP and BCL-6 and TrxA (), or GFP and BCL-6 and Apt48 ('), was measured over 3 days in the absence (a) and presence (b) of interleukin 2 and 5. In the absence of these cytokines, cells expressing BCL-6 alone, or BCL-6 and TrxA appear to have a slight growth advantage at day 2, but this effect, which was not robust, is negligible by day 3. In contrast, in the presence of interleukins, cells expressing GFP alone fail to grow, whereas cells expressing BCL-6 alone grow exponentially. TrxA is without effect on BCL-6-mediated cytokine resistance (), but Apt48 restores cytokine-mediated growth inhibition on BCL-6 expressing cells ('). (c, d and e): Apt48 inhibits the growth of BCL-6 expressing Burkitt's lymphoma cells. Ramos (c), Raji (d) and Daudi cells (e), that constitutively express BCL-6, were transfected with GFP-expression plasmid alone (~), or GFP þ either TrxA () or Apt48 ('). Although TrxA and EGFP appear to have some toxicity in this assay, as cell numbers do not increase over time and in fact decrease with TrxA expression, Apt48 expression leads to a significant decrease in cell viability, from 90% for EGFP expressing cells to 56% for Apt48 (panel c). Similar results were obtained with two other BCL-6 expressing cell lines, Raji (d) and Daudi (e).
promotes the development or growth of lymphomas. However, it was not clear whether inhibition of BCL-6 function would be sufficient to reverse the proliferative phenotype: as a transcriptional regulator, it is possible that changes in gene expression owing to altered BCL-6 function are themselves tumorigenic, and inhibiting BCL-6 may not be able to reverse the effects of these downstream genes.
BCL-6 must homodimerize through its N-terminal POZ domain and recruit corepressor molecules and histone deacetylases to mediate its effects (Dhordain et al., 1998; Huynh and Bardwell, 1998; Ahmad et al., 2003) . We reasoned that disruption of interactions mediated by the POZ domain with small molecules was feasible and likely to result in inhibition of BCL-6 function. Knockout mouse studies in which BCL-6 expression was absent from the earliest stages of development produces impaired primary and secondary T-cell-dependent immune responses and the development of a Th2 inflammatory reaction (Dent et al., 1997; Ye et al., 1997) . The effects of BCL-6 deficiency induced in mature animals, are impossible to predict and at present targeting BCL-6 appears likely to be a route that will provide new treatments for some lymphomas as previously suggested by others (Polo et al., 2004) .
We have taken an open-ended approach to the inhibition of BCL-6, in seeking to identify small proteins that, by binding to the POZ domain, would inhibit BCL-6 function and allow the expression of genes usually repressed by BCL-6. We concentrated on the inhibitor, called Apt48, whose strength of interaction with BCL-6 is comparable to that of the native proteinprotein interaction of the POZ domain itself in the yeast two-hybrid format. Apt48 is able to reverse BCL-6 mediated repression of three target genes in our hands (CD69, Blimp-1 and cyclin D2).
We have evaluated Apt48 in six different cell lines, that either do not express endogenous BCL-6 (U2os, BCL-1), or express pathological levels of BCL-6 (mouse A20, human Burkitt's lymphoma lines Ramos, Raji and Daudi). In U2os cells, we show that Apt48 can interact with transfected, overexpressed BCL-6. We use the cytokine-responsiveness of BCL-1 cells to show that Apt48 can restore cytokine-mediated induction of gene expression at a promoter otherwise repressed by BCL-6. In Ramos and A20 cells, we show that Apt48 can lead to the de-repression of three genes that are known targets of BCL-6-mediated repression. Finally, we show that Apt48 can restore clinically relevant growth arrest to BCL-6 overexpressing lymphoma cells.
The BBD peptide derived from the portion of the SMRT corepressor that binds to BCL-6 has recently been shown to be able to inhibit BCL-6 function (Polo et al., 2004) . It was important to find out whether the mechanism of action of Apt48 involves inhibition of SMRT binding at the site occupied by the BBD peptide. However, when we tried to alter the amino-terminal sequences of the random portion of Apt48 to more closely resemble the SMRT sequence, we found that interaction with BCL-6 POZ was lost (data not shown). Conversely, a mutation in BCL-6 POZ that inhibits the recruitment of the SMRT-derived peptide does not inhibit recruitment of Apt48 (Figure 2b ). Finally, we mapped the interaction site of Apt48 on BCL-6 POZ to an 18-amino-acid residue fragment that contributes two strands of b sheet at the top of the POZ monomer in the structure, and falls within a region surrounding the charged pocket (Ahmad et al., 2003;  Figure 2c) . The BBD peptide, in both the structure and in our yeast twohybrid mapping experiment, binds at the opposite end of the molecule. We conclude that Apt48 is binding to BCL-6 in a manner distinct from that used by SMRT, in a region of b sheet at the top of the molecule. Further experiments involving site-directed mutagenesis of this region in the POZ construct both in yeast and mammalian systems will be required to verify this. The ability of full-length POZ to interact with this region (Figure 2c ) is suggestive of a topological surface capable of recognizing some orientation(s) of a POZ domain. Keeping in mind that this region is close in proximity to the charged pocket at the top of the molecule that has previously been suggested to serve as a protein interaction site (Melnick et al., 2002) , it is quite likely that the region may be part of a binding site of yet uncharacterized interaction partners, perhaps containing POZ domains themselves. The ability of Apt48 to bind to this region may represent a novel mechanism of action where it sterically competes or displaces native interactors required for proper functioning of BCL-6. Thus, our open-ended approach has led us to identify a new way to interfere with BCL-6 function, distinct from that used by Polo et al. (2004) .
The exact mechanism of action of Apt48 remains to be identified. It is a possibility that Apt48 may compete for binding with a region of SMRT (or another corepressor) that makes contact at the top of the molecule. However, although such an interaction has been implied (Melnick et al., 2002) , experimental proof for such an interaction is lacking (Ahmad et al., 2003) . It is a formal possibility that Apt48 may inhibit DNA binding by full-length BCL-6. However, POZ domains have been suggested to inhibit DNA binding by the carboxy-terminal zinc-finger domain (Bardwell and Treisman, 1994) , so that it might be anticipated that Apt48 will increase sequence-specific DNA binding by the zinc-finger domain.
The corepressors N-CoR and SMRT recruit histone deacetylase in order to accomplish transcriptional repression (Cattoretti et al., 1995) , but more recently other interacting repressor proteins have been identified. ETO binds to the fourth zinc finger of BCL-6 (Chevallier et al., 2004) and also recruits histone deacetylase and the Mi-2/NURD corepressor complex associates with its central region. This means of mediating transcriptional repression was shown to be functionally significant in reprogramming B-cell differentiation (Fujita et al., 2004) . Thus, although the efficacy of blocking the SMRT/BCL-6 interaction has been shown (Polo et al., 2004) there is likely to be therapeutic value in employing other means of abrogating BCL-6 function, and we suggest that Apt48 will be a useful tool in developing these agents.
This work has validated a novel surface of BCL-6 as a therapeutic target in vivo. Our ultimate goal is to turn Apt48 into a clinically useful drug. There are several independent strategies for achieving this goal. The most straightforward would be to identify drug-like small molecules that mimic the effect of Apt48. A rapid means to identify such molecules would be to first screen for those that can inhibit the binding of Apt48 to BCL-6 POZ, then to ask which of these are able to antagonize BCL-6 function.
